Compare PAGSEG Inc (PAGS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PAGSEG Inc vs Twist Bioscience Corp — how do they compare? PAGSEG Inc trades at $9.6 (market cap $2.69B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Twist Bioscience Corp is far larger — about 3.1× PAGSEG Inc's market cap, and PAGSEG Inc pays a 11.49% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| PAGS | TWST | |
|---|---|---|
Market Cap | $2.69B | $8.42B |
Sector | Technology | Health |
52-Week High | $12.00 | $153.10 |
52-Week Low | $8.44 | $24.16 |
Enterprise Value | $10.60B | $8.35B |
Dividend Yield | 11.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PAGS trades at $9.75, up 0.21% today, with a bullish technical signal from moving averages and a consensus analyst price target of $11.45. The company reported Q2 2026 EPS of $0.41, beating expectations, and maintains solid fundamentals with a P/E of 6.67 and net income margin of 10.45%. Recent news highlights institutional investments and management continuity despite leadership changes.
The outlook is positive with attractive valuation and growth potential, but risks include macroeconomic challenges in Brazil and competitive pressures. Upside is supported by analyst buy ratings and dividend payments, though investors should monitor credit loss trends and interest rate impacts on profitability.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
